Denosumab and Calcium Homeostasis in Hypercalcaemia of Malignancy and Primary Hyperparathyroidism
International Journal of Endocrinology · 2026-01 · 2026 (1)
DOI: 10.1155/ije/6930716 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Endocrinology, online erschienen am 10.11.2026. Verfasst von Fengye Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy The Affiliated Hospital of Inner Mongolia Medical University Hohhot 010059 Inner Mongolia China nmgfy.com. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Inner Mongolia, Inner Mongolia Medical University.
Abstract (Originalsprache)
Purpose
To evaluate short‐term changes in serum calcium and the occurrence of values below prespecified thresholds after denosumab treatment in institutional oncology and primary hyperparathyroidism (PHPT) cohorts, and to interpret these findings within the context of FAERS reporting patterns and published PHPT evidence.
Methods
We retrospectively analysed denosumab‐treated patients at the Affiliated Hospital of Inner Mongolia Medical University; the retrospective study was performed in the Department of Clinical Pharmacy (oncology cohort, 2024; PHPT cohort, 2022–April 2025). Total serum calcium was evaluated at baseline and around Days 3 and 7. A downstream FAERS reanalysis used the fixed 2014Q1–2023Q2 dataset, and published PHPT reports were re‐extracted for actual follow‐up and complications.
Results
In the oncology subgroup with baseline calcium > 2.55 mmol/L, mean paired calcium changed from 3.101 to 2.278 mmol/L at Day 3 ( n = 12; p = 0.0002) and from 3.158 to 1.990 mmol/L at Day 7 ( n = 11; p < 0.0001). In PHPT, the corresponding changes were 3.376 to 2.661 mmol/L at Day 3 ( n = 9; p = 0.0038) and 3.351 to 2.289 mmol/L at Day 7 ( n = 8; p = 0.0013). During Days 1–10, calcium < 2.10 mmol/L occurred in 57/102 oncology patients with non‐low baseline calcium and 4/9 PHPT patients; values < 1.60 mmol/L occurred in 3/102 and 0/9, respectively. Among 1433 FAERS hypocalcaemia reports, 1186 (82.76%) had at least one serious‐outcome code, most often hospitalisation/prolonged hospitalisation (769; 53.66%) or another medically important condition (725; 50.59%). Crude hypocalcaemia reporting proportions were higher for 120 mg than 60 mg, for male than female reports, and for tumour‐related than osteoporosis indications; the youngest evaluable age strata also had higher proportions, but denominators were small, and the comparisons were unadjusted.
Conclusion
In the analysed cohorts, denosumab was followed by short‐term calcium reduction in patients with baseline hypercalcaemia and in the small PHPT cohort. Values below 2.10 mmol/L were common in early follow‐up, whereas values below 1.60 mmol/L were uncommon, and clinical hypocalcaemia was not systematically adjudicated. FAERS hypocalcaemia reports often carried serious‐outcome codes, mainly hospitalisation and other medically important conditions, without establishing incidence, causality or independent risk factors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy The Affiliated Hospital of Inner Mongolia Medical University Hohhot 010059 Inner Mongolia China nmgfy.com.
- Graduate School Inner Mongolia Medical University Hohhot 010059 Inner Mongolia China immu.edu.cn.
- Department of Endocrinology The Affiliated Hospital of Inner Mongolia Medical University Hohhot 010059 Inner Mongolia China nmgfy.com.
ORCID-Profile: Fengye Zhou, Ying Liu, Chunfang Liang, Sufang Yun
Förderung
- Natural Science Foundation of Inner Mongolia
- Inner Mongolia Medical University
Zitieren
APA
Zhou, F., Liu, Y., Liang, C., & Yun, S. (2026). Denosumab and Calcium Homeostasis in Hypercalcaemia of Malignancy and Primary Hyperparathyroidism. International Journal of Endocrinology, 2026(1). https://doi.org/10.1155/ije/6930716
Vancouver
Zhou F, Liu Y, Liang C, Yun S. Denosumab and Calcium Homeostasis in Hypercalcaemia of Malignancy and Primary Hyperparathyroidism. International Journal of Endocrinology. 2026;2026(1). doi:10.1155/ije/6930716
BibTeX
@article{Zhou2026,
author = {Zhou, Fengye and Liu, Ying and Liang, Chunfang and Yun, Sufang},
title = {Denosumab and Calcium Homeostasis in Hypercalcaemia of Malignancy and Primary Hyperparathyroidism},
journal = {International Journal of Endocrinology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ije/6930716}
}
EUVIMED